Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.54 |
| ▸ | SLC9A3 | P48764 | 9/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8165904 | 1.00 | HTR1A (0.54) | HTR1ASLC9A3CHRNA7TSHRSLC18A3 | |
| SCHEMBL8165906 | 1.00 | HTR1A (0.54) | HTR1ASLC9A3CHRNA7TSHRSLC18A3 | |
| SCHEMBL12362861 | 0.85 | HTR1A (0.57) | HTR1A | |
| SCHEMBL10699110 | 0.81 | SLC9A3 (0.45) | SLC9A3CHRNA7TSHRSLC18A3 | |
| SCHEMBL7625381 | 0.81 | SLC18A3 (0.53) | HTR1ACHRNA7SLC18A3 | |
| SCHEMBL9748475 | 0.79 | SLC18A3 (0.65) | SLC18A3 | |
| SCHEMBL9748459 | 0.79 | SLC18A3 (0.65) | SLC18A3 | |
| SCHEMBL9748466 | 0.79 | SLC18A3 (0.65) | SLC18A3 | |
| SCHEMBL18098658 | 0.79 | SLC9A3 (0.49) | SLC9A3CHRNA7TSHR | |
| SCHEMBL28806320 | 0.79 | SLC9A3 (0.48) | SLC9A3CHRNA7TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550788-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2017-01-24 | — | — | US | disclosed |
| US-9550788-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2017-01-24 | — | — | US | disclosed |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2014-11-27 | — | — | US | disclosed |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2014-11-27 | — | — | US | disclosed |
| US-8822449-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| US-8822449-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| US-20110201590-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | disclosed |
| US-20110201590-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201590-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | CFTR, AADAT, PKD1 | HTR1A 1026/4885SLC9A3 750/4885CHRNA7 3993/4885 |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | CFTR, AADAT, FANCI | HTR1A 907/4885SLC9A3 930/4885CHRNA7 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.